JNCE News and Press, Jounce Therapeutics Inc. From 04/28/22

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2022 financial result...

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside c...

Gainers: Burning Rock Biotech Limited (BNR) +5%. Hemisphere Media Group (HMTV) +4%. Neuronetics  (STIM) +4%. AvePoint  (AVPT) +3%. Jounce Therapeutics (JNCE) +3%. Losers: UroGen Pharma (URGN) -12%. Purple Innovation  (PRPL) -5%. Trinity Capital  (TRIN) -4%. ...

Gainers: Sportradar Group AG (SRAD) +5%. Eargo, Inc. (EAR) +4%. Zynex, Inc. (ZYXI) +3%. IVERIC bio, Inc. (ISEE) +3%. Sono Group N.V. (SEV) +3%. Losers: Vir Biotechnology, Inc. (VIR) -8%. Jounce Therapeutics, Inc. (JNCE) -6%. Travelzoo (TZOO) -5%. Health Catalyst, Inc (HCAT) -4%...

Gainers: Eiger BioPharmaceuticals (EIGR) +36%. Cyteir Therapeutics (CYT) +30%. PAVmed (PAVM) +28%. Cingulate (CING) +26%. Bone Biologics (OTCPK:BBLG) +22%. Losers: Incannex Healthcare Limited (IXHL) -12%. Jounce Therapeutics (JNCE) -9%. Rapid Micro Biosystems (RPID) -...

SMBC Nikko has initiated shares of Jounce Therapeutics (JNCE +3.2%) with an outperform rating due to the promise of its lead immuno-oncology candidate, JTX-8064. JTX-8064 is an anti-Leukocyte Immunoglobulin Like Receptor B2 (LILRB2)/ILT4 antibody for solid tumors currently in phase 1/2. ...

Jounce Therapeutics, Inc. (JNCE) Q4 2021 Earnings Conference Call March 2, 2022 08:00 ET Company Participants Eric Laub - Vice President of Investor Relations Richard Murray - President & Chief Executive Officer Beth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer Dmit...

The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Jounce Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Jounce Therapeutics press release (NASDAQ:JNCE): Q4 GAAP EPS of -$0.59 misses by $0.27. As of December 31, 2021, cash, cash equivalents and investments were $220.2 million, compared to $213.2 million as of December 31, 2020. FY22 Guidance: Gross cash burn on operating expenses and c...

- Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody targeting LILRB4, enters IND-enabling activities representing the fifth internally discovere...